

• Substitute for form 1449A/PTO

INFORMATION DISCLOSURE



STATEMENT BY APPLICANT

Oct 17 2005
(use as many sheets as necessary)

Substitute for form 1449A/PTO		COMPLETED / UNKNOWN	
INFORMATION DISCLOSURE		Application Number	10/542,214
STATEMENT BY APPLICANT		Filing Date	July 14, 2005
(use as many sheets as necessary)		First Named Inventor	Wallace T. Ashton, et al.
		Group Art Unit	
		Examiner Name	
Sheet	1	of	5
		Attorney Docket Number	21317YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
CA	9	PCT	WO 03/082817 A2		MERCK & CO., INC.	10/09/2003
CA	10	PCT	WO 03/000180 A2		MERCK & CO., INC.	01/03/2003
CA	11	PCT	WO 03/000181 A2		MERCK & CO., INC.	01/03/2003
CA	12	PCT	WO 03/000181 A3		MERCK & CO., INC.	01/03/2003
CA	13	PCT	WO 02/076450 A1		MERCK & CO., INC.	10/03/2002
CA	14	PCT	WO 2004/007468 A1		MERCK & CO., INC.	01/22/2004
CA	15	PCT	WO 2004/032836 A2		MERCK & CO., INC.	04/22/2004
CA	16	PCT	WO 2004/050022 A2		MERCK & CO., INC.	06/17/2004
CA	17	PCT	WO 2004/058266 A1		MERCK & CO., INC.	07/15/2004
CA	18	PCT	WO 2004/064778 A2		MERCK & CO., INC.	08/05/2004

Examiner Signature	<i>AISLAKH</i>	Date Considered	<i>3/9/07</i>
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Do not initial in blank spaces.			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				COMPLETE KNOWN	
				Application Number	10/542,214
				Filing Date	July 14, 2005
				First Named Inventor	Wallace T. Ashton, et al.
				Group Art Unit	
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	21317YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
CA	19	PCT	WO 2004/069162 A2		MERCK & CO., INC.	08/19/2004
CA	20	PCT	WO 02/02560 A2		NOVO NORDISK A/S	01/10/2002
CA	21	PCT	WO 01/96295 A2		NOVARTIS AG	12/20/2001
CA	22	PCT	WO 01/96295 A3		NOVARTIS AG	12/20/2001
CA	23	PCT	WO 01/34594 A1		Guilford Pharmaceuticals, Inc.	05/17/2001
CA	24	PCT	WO 00/34241		NOVARTIS AG	06/15/2000
CA	25	PCT	WO 98/19998 A2		NOVARTIS AG	05/14/1998
CA	26	PCT	WO 98/19998 A3		NOVARTIS AG	05/14/1998
CA	27	PCT	WO 97/40832		Hansknoll-Institut Fur Naturstoff-Forschung E.V.	11/06/1997
CA	28	PCT	WO 03/000180 A3		MERCK & CO., INC.	01/03/2003

Examiner Signature	ALLAKA	Date Considered	3/9/07
-----------------------	--------	--------------------	--------

SEND TO: Commissioner for Patents P. O. Box 1450 Alexandria VA 22313-1450

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

9

5

Attorney Docket Number 21317YP

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
CA	29	PCT	WO 02/02560	A3	NOVO NORDISK	01/10/2002
CA	30	PCT	WO 01/42262		AKZO NOBEL N.V.	06/14/2001
CA	31	PCT	WO 2004/043940		MERCK & CO., INC.	05/27/2004
CA	32	PCT	WO 2004/007468		MERCK & CO., INC.	01/22/2004
CA	33	PCT	WO 2004/110436		MERCK & CO., INC.	12/23/2004
CA	34	PCT	WO 2004/112701	A2	MERCK & CO., INC.	12/29/2004
CA	35	PCT	WO 2004/112701	A3	MERCK & CO., INC.	12/29/2004
CA	36	PCT	WO 2005/011581	A2	MERCK & CO., INC.	02/10/2005
CA	37	PCT	WO 2005/044195	A2	MERCK & CO., INC.	05/19/2005
CA	38	PCT	WO 2005/002530	A2	SMITHKLINE BEECHAM CORP.	01/09/2003

[Redacted]

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of his form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Comments received from "IDS Form," (IDS Folder), Merck & Co., Inc., 7/12/2005

*** Substitute for form 1449A/PTO**

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				COMPLETE UNKNOWN	
				Application Number	10/542,214
				Filing Date	July 14, 2005
				First Named Inventor	Wallace T. Ashton, et al.
				Group Art Unit	
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	21317YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	AISLAKI	Date Considered	319/07
-----------------------	---------	--------------------	--------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder). Merck & Co., Inc. - 7/12/2001

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE UNKNOWN	
Sheet	5	of	5	Application Number	10/542,214
				Filing Date	July 14, 2005
				First Named Inventor	Wallace T. Ashton, et al.
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	21317YP

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.			
CA	41	J. J. Holst, "Treatment of Type 2 Diabetes Mellitus with Agonists of the GLP-1 Receptor or DPP-IV Inhibitors", Expert Opin. Emerg. Drugs, Vol. 9(1) pp. 155-166, 2004.			
CA	42	C. F. Deacon, et al., "Inhibitors of dipeptidyl peptidase IV: A Novel Approach for the Prevention and Treatment of Type 2 Diabetes?", Expert Opin. Investig. Drugs, Vol. 13(9) pp. 1091-1102, 2004.			
CA	43	K. Augustyns et al., "Dipeptidyl Peptidase IV Inhibitors as New Therapeutic Agents for the Treatment of Type 2 Diabetes", Expert Opin. Ther. Patents, Vol. 13(4), pp. 499-510, 2003.			
CA	44	Novartis AG: WO0034241, "Novel N-substituted-2-Cyanopyrrolidines as Potent Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Non-Insulin-Dependent Diabetes Mellitus", Exp. Opin. Ther. Patents, Vol. 10(12), pp. 1937-1942, 2000.			
CA	45	O. J. Orucker, "Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes", Exp. Opin Invest. Drugs, Vol. 12, 2004, pages 87-100.			
CA	46	T. P. Vahl & D. A. D'Alessio, "Gut peptides in the treatment of diabetes mellitus" Exp. Opin. Invest. Drugs, Vol. 13, 2004, pages 177-188.			
CA	47	L. B. Knudsen, "Glucagon-like peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes", J. Med. Chem. Vol. 47, 2004, pages 4128-4134.			
CA	48	Ann E. Weber, "Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes", J. Med. Chem. Vol. 47, 2004, pages 4135-4141.			
CA	49	J. J. Holst and C. F. Deacon, "Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus", Curr. Opin Pharmacology, Vol. 4, 2004, pages 589-596.			
CA	50	C. F. Deacon, "Perspectives in Diabetes - Therapeutic Strategies Based on Glucagon-Like Peptide 1", Diabetes, Vol. 53, Sept. 2004, pages 2181-2189.			
CA	51	Kuroki, et al, Database CAPLUS on STN No. 130:1685654, 1999			
CA	52	Burger, A Guide to the Chemical Basis of Drug Design, page 15 (1983)			

Examiner Signature	Allach	Date Considered	3/9/07
--------------------	--------	-----------------	--------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 7/12/2005